lorlatinib
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
June, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
lorlatinib
Jun 17, 2024, 04:08 |
Insight
Sergio Cifuentes: Key Changes to My Oncology Practice from ASCO2024
Sergio Cifuentes, Cancer Research Project Manager at CENEIT México, shared a post on X: "My…
Jun 15, 2024, 15:32 |
Blog
Yüksel Ürün: As a GU oncologist my non-GU key highlights from ASCO24
Yüksel Ürün shared on X/Twitter: "As a GU oncologist my non-GU key highlights from ASCO24. 1.…
Jun 2, 2024, 11:16 |
Insight
Giannis Mountzios: Lorlatinib in ALK positive NSCLC sets a new benchmark in Precision Oncology
Giannis Mountzios, Medical Oncologist at the Department of Medical Oncology in the Air Force General…
Jun 1, 2024, 12:55 |
Societies
Day 1 ASCO24 Highlights by Oncology Brothers
Oncology Brothers shared on X: Day 1 ASCO24 Highlights: 1. CROWN: Lorlatinib in ALK mNSCLC…
May 27, 2024, 04:19 |
Opinion
Gilberto Lopes: My top ASCO24 lung cancer abstracts!
Gilberto Lopes, Chief of the Division of Medical Oncology at Sylvester Comprehensive Cancer Center, shared…
May 5, 2024, 01:02 |
Blog
Amol Akhade: Does this ring bell for other oral drugs also?
Amol Akhade, Consultant Medical Oncologist at Suyog Cancer Clinics, shared a post on X: “Optimal…
All:
6
Posts:
1 - 10
New Paper Alert! Long-Term Benefits of Dabrafenib-Trametinib in Stage III Melanoma: 8-Year COMBI-AD Trial Results
We mourn the loss of our Ivy Elkins
FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer
Rob Winn: Honored to receive the ASCO Allen Lichter Visionary Leader Award
Yardena Samuels: An absolute honor to be elected as the next EACR president
Facebook
RSS Feed
Twitter
Linkedin
Youtube